Jade Biosciences, Inc. (JBIO) Income Statement
JBIO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsJBIO revenue and net income
JBIO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
JBIO quarterly EPS vs estimates
Jade Biosciences beat the analyst EPS estimate in 1 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.73).
JBIO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $26,000 | $282,000 | $96,000 | $68,000 | $15,000 | $1,000 |
| Gross profit | −$26,000 | −$282,000 | −$96,000 | −$68,000 | −$15,000 | −$1,000 |
| Research & development | $93.1M | $53.2M | $64.2M | $38.6M | $15.0M | $7.9M |
| Sales, general & admin | $20.4M | $8,608 | — | — | — | — |
| Total operating expenses | $113.5M | $74.3M | $81.3M | $53.2M | $23.0M | $8.9M |
| Operating income | −$113.5M | −$74.6M | −$81.4M | −$53.2M | −$23.0M | −$8.9M |
| Interest income | $7.8M | — | — | — | — | — |
| Interest expense | — | — | — | — | — | $75,000 |
| Income before taxes | −$127.4M | −$69.6M | −$75.5M | −$51.5M | −$23.0M | −$9.6M |
| Income taxes | $58,000 | $55,000 | $56,000 | $25,000 | $3,000 | — |
| Net income | −$127.4M | −$69.6M | −$75.5M | −$51.5M | −$23.0M | −$9.6M |
| EBITDA | −$127.3M | −$69.3M | −$75.4M | −$51.4M | −$22.9M | −$9.5M |
| EPS (diluted) | −$13.44 | −$57.14 | −$28.04 | −$54.81 | −$866.77 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $9,000 | $9,000 | $9,000 | $12,000 | $1,000 | $4,000 | $8,000 | $218,000 | $28,000 | $28,000 | $28,000 | $25,000 |
| Gross profit | −$9,000 | −$9,000 | −$9,000 | −$12,000 | −$1,000 | −$4,000 | −$8,000 | −$218,000 | −$28,000 | −$28,000 | −$28,000 | −$25,000 |
| Research & development | $50.1M | $36.1M | $28.5M | $22.0M | $22.5M | $20.0M | $1.5M | $13.6M | $21.2M | $20.1M | $17.8M | $16.9M |
| Sales, general & admin | $8.9M | $7.4M | $6.4M | $5.4M | $5.2M | $3.4M | $2.4M | $1.4M | — | — | — | — |
| Total operating expenses | $58.9M | $43.4M | $35.0M | $27.4M | $27.8M | $3.4M | $6.4M | $15.0M | $26.1M | $24.6M | $22.0M | $21.3M |
| Operating income | −$58.9M | −$43.4M | −$35.0M | −$27.4M | −$27.8M | −$3.4M | −$6.4M | −$15.0M | −$26.2M | −$24.6M | −$22.1M | −$21.4M |
| Interest income | $3.2M | $3.1M | $3.1M | $2.3M | $1.8M | $615,000 | $771,000 | $388,000 | — | — | — | — |
| Income before taxes | −$55.8M | −$40.4M | −$31.9M | −$25.2M | −$32.1M | −$2.5M | −$5.4M | −$16.3M | −$24.8M | −$23.2M | −$20.4M | −$19.6M |
| Income taxes | $15,000 | $16,000 | $58,000 | — | — | — | $55,000 | — | — | — | $56,000 | — |
| Net income | −$55.8M | −$40.4M | −$31.9M | −$25.2M | −$32.1M | −$2.5M | −$5.4M | −$16.3M | −$24.8M | −$23.2M | −$20.4M | −$19.6M |
| EBITDA | −$58.9M | −$40.3M | −$31.9M | −$25.2M | −$32.1M | −$2.5M | −$5.4M | −$16.3M | −$24.7M | −$23.2M | −$20.3M | −$19.5M |
| EPS (diluted) | −$0.76 | −$0.57 | — | −$0.48 | −$0.86 | −$12.10 | −$6.61 | −$19.60 | −$30.10 | −$0.83 | −$25.90 | −$0.71 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in JBIO's financial statements (latest annual report filed March 6, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
JBIO financial results
Jade Biosciences reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $127.4 million. Diluted earnings per share came to −$13.44.
See the JBIO stock overview for the latest quote and news, or the JBIO chart for price history and technical indicators.
JBIO income statement FAQ
Does Jade Biosciences have revenue?
Jade Biosciences reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Jade Biosciences profitable?
No. Jade Biosciences reported a net loss of $127.4 million in fiscal 2025.
How much does Jade Biosciences spend on research and development?
Jade Biosciences spent $93.1 million on research and development in fiscal 2025.
What are Jade Biosciences's earnings per share?
Jade Biosciences earned $-13.44 per diluted share in fiscal 2025, compared with $-57.14 a year earlier.
When will Jade Biosciences report its next earnings?
Jade Biosciences is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens.
When does Jade Biosciences's fiscal year end?
Jade Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 6, 2026.